AU2022388745A1 - Microbial compositions for the treatment of skin diseases - Google Patents

Microbial compositions for the treatment of skin diseases Download PDF

Info

Publication number
AU2022388745A1
AU2022388745A1 AU2022388745A AU2022388745A AU2022388745A1 AU 2022388745 A1 AU2022388745 A1 AU 2022388745A1 AU 2022388745 A AU2022388745 A AU 2022388745A AU 2022388745 A AU2022388745 A AU 2022388745A AU 2022388745 A1 AU2022388745 A1 AU 2022388745A1
Authority
AU
Australia
Prior art keywords
composition
strain
seq
sequence
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022388745A
Other languages
English (en)
Inventor
Cheri ACKERMAN
Keaton ARMENTROUT
Bernardo CERVANTES
Abdulrahman HASSABALLAH
Jared KEHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concerto Biosciences Inc
Original Assignee
Concerto Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concerto Biosciences Inc filed Critical Concerto Biosciences Inc
Publication of AU2022388745A1 publication Critical patent/AU2022388745A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2022388745A 2021-11-11 2022-11-10 Microbial compositions for the treatment of skin diseases Pending AU2022388745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278134P 2021-11-11 2021-11-11
US63/278,134 2021-11-11
PCT/US2022/079637 WO2023086883A1 (en) 2021-11-11 2022-11-10 Microbial compositions for the treatment of skin diseases

Publications (1)

Publication Number Publication Date
AU2022388745A1 true AU2022388745A1 (en) 2024-05-30

Family

ID=86336611

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022388745A Pending AU2022388745A1 (en) 2021-11-11 2022-11-10 Microbial compositions for the treatment of skin diseases

Country Status (8)

Country Link
US (3) US12115197B2 (https=)
EP (1) EP4429683A1 (https=)
JP (1) JP2024544960A (https=)
KR (1) KR20240117164A (https=)
CN (1) CN118541163A (https=)
AU (1) AU2022388745A1 (https=)
CA (1) CA3237750A1 (https=)
WO (1) WO2023086883A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660645C (en) 2006-08-11 2016-04-05 Novozymes Biologicals, Inc. Bacillus cultures for use in washing, cleaning, stain removal, or degrading waste materials
KR100878799B1 (ko) * 2007-03-13 2009-01-14 한국생명공학연구원 항생제 내성 병원성 미생물 또는 장내 유해 미생물의생장을 억제하는 바실러스 아밀로리퀴페시언스 ｋ317
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US20160073642A1 (en) 2013-05-03 2016-03-17 Universidad Eafit Production process for biomass and fengycin metabolites of bacillus species and compositions thereof for biological pest control
US20180289751A1 (en) * 2015-05-05 2018-10-11 The Regents Of The University Of California Antimicrobial therapy
WO2018049182A2 (en) 2016-09-08 2018-03-15 Locus Solutions, Llc Distributed systems for the efficient production and use of microbe-based compositions
KR20190140063A (ko) 2017-05-07 2019-12-18 로커스 아이피 컴퍼니 엘엘씨 피부 건강을 위한 화장품 조성물 및 이를 사용하는 방법
EP3784807B1 (en) 2018-04-23 2025-06-04 Evonik Operations GmbH Synbiotic compositions
US20220096574A1 (en) 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
JP7689077B2 (ja) 2019-02-11 2025-06-05 エボニック オペレーションズ ゲーエムベーハー バシラエン産生細菌またはその調製物を含有する組成物
MX2021012558A (es) * 2019-04-17 2022-01-04 Andes Ag Inc Metodos innovadores para el tratamiento de las semillas y componentes para mejorar los atributos y el rendimiento de la planta.
BR112021023020A2 (pt) 2019-05-20 2022-01-04 Evonik Operations Gmbh Uso de ésteres de poliglicerol como carreador para ingredientes microbiológicos ativos
MX2021015725A (es) 2019-06-19 2022-04-01 Basf Corp Formulaciones agroquimicas acuosas que comprenden esporas de bacterias.
GB201911925D0 (en) 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
CA3187427A1 (en) 2020-06-17 2021-12-23 Bioconsortia, Inc. Agriculturally beneficial microbes, microbial compositions, and consortia
EP4223301A1 (en) 2020-09-07 2023-08-09 Il Dong Pharmaceutical Co., Ltd. Composition for preventing or treating periodontal diseases, comprising bacillus velezensis strain, culture medium thereof, or culture supernatant thereof as active ingredient
JP2023543355A (ja) 2020-09-25 2023-10-13 バイオームエディット・エルエルシー プロバイオティックバチルス属組成物及び使用方法
WO2022119895A1 (en) 2020-12-01 2022-06-09 Dupont Us Holding, Llc Methods and compositions for microbial treatment of skin disorders
IL305939A (en) 2021-03-14 2023-11-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Bacillus antibacterial agents
WO2022226376A2 (en) 2021-04-22 2022-10-27 Indigo Ag, Inc. Endophyte compositions and methods for improved plant health
WO2023091342A1 (en) 2021-11-16 2023-05-25 Phibro Animal Health Corporation Preservation system for stabilizing spore-forming microbials

Also Published As

Publication number Publication date
US12329787B2 (en) 2025-06-17
WO2023086883A1 (en) 2023-05-19
US20240424033A1 (en) 2024-12-26
JP2024544960A (ja) 2024-12-05
US12115197B2 (en) 2024-10-15
CA3237750A1 (en) 2023-05-19
US20250268955A1 (en) 2025-08-28
US20240189369A1 (en) 2024-06-13
KR20240117164A (ko) 2024-07-31
EP4429683A1 (en) 2024-09-18
CN118541163A (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
US11590092B2 (en) Skin probiotic
Zilliox et al. Assessing the ocular surface microbiome in severe ocular surface diseases
JP2012070745A (ja) 病原微生物から皮膚を保護するための方法および手段
US20250222045A1 (en) Bifidobacterium longum subsp. infantis, microbial agent and use thereof
KR20210102871A (ko) 여드름 치료를 위한 프로프리오니박테리움 아크네스에 대한 세균 요법
Sav et al. The frequency, antifungal susceptibility and enzymatic profiles of Candida species in cases of onychomycosis infection
Shah et al. Role of polyamine transport in Streptococcus pneumoniae response to physiological stress and murine septicemia
de Moragas et al. Cutaneous alternariosis treated with miconazole
US12329787B2 (en) Microbial compositions for the treatment of skin diseases
CN116019839A (zh) 乳酸肠球菌jdm1在制备预防或治疗炎症性肠病的药物中的应用
CN119700821A (zh) 表皮葡萄球菌h62-3活菌制剂在制备预防或治疗银屑病的药物中的应用
Kush et al. Evaluation of antimicrobial action of Carie Care™ and Papacarie Duo™ on Aggregatibacter actinomycetemcomitans a major periodontal pathogen using polymerase chain reaction
AL-Hasseny et al. Molecular Detection of nan, tly and dsA gene of Propionibacterium acnes Isolated from acne vulgaris in Babylon Province
CN114259493A (zh) 一种抑制沙门氏菌外排泵的抗生素佐剂及类似物的应用
Mishra et al. Quantitative and rapid antibacterial assay of Micromeria biflora Benth. leaf essential oil against dental caries causing bacteria using phylogenetic approach
Kim et al. Distinct Cutibacterium acnes subspecies defendens strains classified by multi-omics dissection alleviate inflammatory skin lesions of a rosacea-like mouse model
EP4527399A1 (en) Composition for treating ringworm
KR102544440B1 (ko) 피부 상재균으로부터 유래된 엔테로박터 에어로게네스 j2k-739 균주 및 피부 상재균 유래 엔테로박터속을 자극원으로 처리하는 신규한 항주름평가 방법
Hooper et al. 522 Skin microbiome in cutaneous T-cell lymphoma is associated with phototherapy treatment response
Park et al. Inhibitory effects of oral probiotics on biofilm formation, growth, and filament development in Candida albicans
Nakatsuji et al. 525 How the inappropriate innate immune response of atopic dermatitis promotes dysbiosis of the skin microbiome
Meyrignac et al. 521 Development of 3D reconstructed skin models with PBMC-derived immune cells
Ramezani et al. Inhibitory effects of cell-free supernatant of Bifidobacterium bifidum on biofilm formation and virulence gene expression in Group B Streptococcus clinical isolates
HK40121821A (zh) 白癣治疗用组合物
EP4680718A1 (en) Skin archaea preparation